Georg Auzinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Georg Auzinger has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Andre Vercueil
Department of Critical Care/ECMO Service, King's College Hospital, London, United Kingdom
3 shared publicationsChristopher Willars
Department of Critical Care/ECMO Service, King's College Hospital, London, United Kingdom
3 shared publicationsJulia Wendon
3 shared publicationsThomas Best
Department of Critical Care/ECMO Service, King's College Hospital, London, United Kingdom
3 shared publicationsChris Willars
King’s College Hospital
2 shared publicationsNigel Heaton
Institute of Liver Studies, King's College Hospital, London, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 27 March 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (4) , e1246
Evaluation of Plasma Biomarkers to Understand the Biology and Heterogeneity of Treatment Effect in Lower Tidal Volume Ventilation Facilitated by Extracorporeal CO2 Removal in Acute Hypoxemic Respiratory Failure: A Secondary Analysis of the REST Trial
OBJECTIVES: In patients with acute hypoxemic respiratory failure (AHRF), the use of lower tidal volume ventilation facilitated by veno-venous extracorporeal CO 2 removal (vv-ECCO2R) does not improve clinical outcomes. The primary objective of this analysis was to evaluate for differences in indices of systemic inflammation and ventilator-induced lung injury between patients treated with lower tidal volume ventilation facilitated by vv-ECCO2R and standard care. Secondary objectives included an evaluation for heterogeneity of treatment effect. DESIGN: Substudy of a randomized clinical trial. SETTING: Nine U.K. ICUs. PATIENTS: Moderate-to-severe AHRF (Pao 2: Fio 2 < 150mmHg [20ka]). INTERVENTION: Plasma samples obtained at baseline and day 3. MEASUREMENTS AND MAIN RESULTS: The primary outcome was day 3 C-reactive protein (CRP). Clinical outcomes included 90-day mortality and ventilator-free days (VFD) until day 28. Exploratory analyses included an evaluation of plasma indices of lung injury, inflammation, and heterogeneity of treatment effect (HTE). Seventy-nine patients were enrolled, and 69 patients had paired plasma samples taken at baseline and day 3. There was no difference in day 3 plasma CRP (intervention 138.6 [70.4, 189.4] vs. standard care 113.0 [62.7, 233.8] mg/L; p = 0.72). Between baseline and day 3, there was a greater increase in plasma interleukin-18 in patients that received intervention compared with those that received standard care (Δ 337.7 [–128.9, 738.9] vs. 6.4 [–457.2, 6.4] pg/mL p = 0.05). In patients with high interleukin-18, allocation to intervention was associated with increased VFDs (p = 0.03). Similarly in patients with a hyperinflammatory phenotype, the intervention was independently associated with increased VFDs (p < 0.01) and decreased 90-day mortality (p = 0.01). CONCLUSIONS: In patients with moderate-to-severe AHRF, lower tidal volume ventilation, facilitated by vv-ECCO2R, was not associated with a difference in day 3 plasma CRP, but was associated with an increase in plasma interleukin-18 between baseline and day 3. Baseline plasma interleukin-18 and inflammatory phenotypes may identify subgroups of patients with moderate-to-severe AHRF that benefit from lower tidal volume ventilation facilitated by vv-ECCO2R. TRIAL REGISTRATION: NCT02654327
- 27 March 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (4) , e1246
Open AccessEvaluation of Plasma Biomarkers to Understand the Biology and Heterogeneity of Treatment Effect in Lower Tidal Volume Ventilation Facilitated by Extracorporeal CO2 Removal in Acute Hypoxemic Respiratory Failure: A Secondary Analysis of the REST Trial
OBJECTIVES: In patients with acute hypoxemic respiratory failure (AHRF), the use of lower tidal volume ventilation facilitated by veno-venous extracorporeal CO 2 removal (vv-ECCO2R) does not improve clinical outcomes. The primary objective of this analysis was to evaluate for differences in indices of systemic inflammation and ventilator-induced lung injury between patients treated with lower tidal volume ventilation facilitated by vv-ECCO2R and standard care. Secondary objectives included an evaluation for heterogeneity of treatment effect. DESIGN: Substudy of a randomized clinical trial. SETTING: Nine U.K. ICUs. PATIENTS: Moderate-to-severe AHRF (Pao 2: Fio 2 < 150mmHg [20ka]). INTERVENTION: Plasma samples obtained at baseline and day 3. MEASUREMENTS AND MAIN RESULTS: The primary outcome was day 3 C-reactive protein (CRP). Clinical outcomes included 90-day mortality and ventilator-free days (VFD) until day 28. Exploratory analyses included an evaluation of plasma indices of lung injury, inflammation, and heterogeneity of treatment effect (HTE). Seventy-nine patients were enrolled, and 69 patients had paired plasma samples taken at baseline and day 3. There was no difference in day 3 plasma CRP (intervention 138.6 [70.4, 189.4] vs. standard care 113.0 [62.7, 233.8] mg/L; p = 0.72). Between baseline and day 3, there was a greater increase in plasma interleukin-18 in patients that received intervention compared with those that received standard care (Δ 337.7 [–128.9, 738.9] vs. 6.4 [–457.2, 6.4] pg/mL p = 0.05). In patients with high interleukin-18, allocation to intervention was associated with increased VFDs (p = 0.03). Similarly in patients with a hyperinflammatory phenotype, the intervention was independently associated with increased VFDs (p < 0.01) and decreased 90-day mortality (p = 0.01). CONCLUSIONS: In patients with moderate-to-severe AHRF, lower tidal volume ventilation, facilitated by vv-ECCO2R, was not associated with a difference in day 3 plasma CRP, but was associated with an increase in plasma interleukin-18 between baseline and day 3. Baseline plasma interleukin-18 and inflammatory phenotypes may identify subgroups of patients with moderate-to-severe AHRF that benefit from lower tidal volume ventilation facilitated by vv-ECCO2R. TRIAL REGISTRATION: NCT02654327
- Open Access
- 4 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (6)
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19
BACKGROUND . Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients’ ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function. METHODS. We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically-ill lymphopenic COVID-19 patients. The primary endpoint was to assess CYT107’s effect on lymphocyte recovery with secondary clinical endpoints including safety, ICU and hospital length-of-stay, incidence of secondary infections, and mortality. RESULTS. CYT107 was well-tolerated without precipitating a cytokine storm or worsening pulmonary function. Absolute lymphocyte counts increased in both groups without significant difference between CYT107 and placebo. COVID-19 patients receiving CYT107 but not concomitant antiviral medications, known inducers of lymphopenia, had a final lymphocyte count that was 43% greater than placebo (p=0.067). There were significantly fewer treatment-emergent adverse events in CYT107 versus placebo-treated patients (pp=0.014). CONCLUSIONS. Given that hospital-acquired infections are responsible for a large percentage of COVID-19 deaths, this effect of CYT107 to decrease nosocomial infections could substantially reduce late morbidity and mortality in this highly lethal disease. The strong safety profile of CYT107 and its excellent tolerability provide support for trials of CYT107 in other potential pandemic respiratory viral infections. TRIAL REGISTRATION. NCT04379076, NCT04426201, NCT04442178, NCT04407689; NCT04927169
- 4 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (6)
Open AccessA randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19
BACKGROUND . Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients’ ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function. METHODS. We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically-ill lymphopenic COVID-19 patients. The primary endpoint was to assess CYT107’s effect on lymphocyte recovery with secondary clinical endpoints including safety, ICU and hospital length-of-stay, incidence of secondary infections, and mortality. RESULTS. CYT107 was well-tolerated without precipitating a cytokine storm or worsening pulmonary function. Absolute lymphocyte counts increased in both groups without significant difference between CYT107 and placebo. COVID-19 patients receiving CYT107 but not concomitant antiviral medications, known inducers of lymphopenia, had a final lymphocyte count that was 43% greater than placebo (p=0.067). There were significantly fewer treatment-emergent adverse events in CYT107 versus placebo-treated patients (pp=0.014). CONCLUSIONS. Given that hospital-acquired infections are responsible for a large percentage of COVID-19 deaths, this effect of CYT107 to decrease nosocomial infections could substantially reduce late morbidity and mortality in this highly lethal disease. The strong safety profile of CYT107 and its excellent tolerability provide support for trials of CYT107 in other potential pandemic respiratory viral infections. TRIAL REGISTRATION. NCT04379076, NCT04426201, NCT04442178, NCT04407689; NCT04927169
- Open Access
- 29 June 2020
- Published by Wiley in Nursing in Critical Care
- Vol. 27 (6) , 784-795
Targeted temperature management in acute liver failure: A systematic review
Background: Targeted temperature management is the modern term for therapeutic hypothermia, where cooling is induced by intensive care clinicians to achieve body temperatures below 36°C. Its use in acute liver failure to improve refractory intracranial hypertension and patient outcomes is not supported by strong quality evidence.Aim: This systematic review aims to determine if targeted temperature management improves patient outcome as opposed to normothermia in acute liver failure.Methods: A computerized and systematic search of six academic and medical databases was conducted using the following keywords: “acute liver failure", “fulminant hepatic injury", “targeted temperature management", “therapeutic hypothermia", and “cooling". Broad criteria were applied to include all types of primary observational studies, from case reports to randomized controlled trials. Standardized tools were used throughout to critically appraise and extract data.Findings: Nine studies published between 1999 and 2016 were included. Early observational studies suggest a benefit of targeted temperature management in the treatment of refractory intracranial hypertension and in survival. More recent controlled studies do not show such a benefit in the prevention of intracranial hypertension. All studies revealed that the incidence of coagulopathy is not higher in patients treated with targeted temperature management. There remains some uncertainty regarding the increased risk of infection and dysrhythmias. Heterogeneity was found between study types, design, sample sizes, and quality.Conclusion: Although it does not significantly improve survival, targeted temperature management is efficient in treating episodes of intracranial hypertension and stabilizing an unstable critical care patient without increasing the risk of bleeding. It does not, however, prevent intracranial hypertension. Data heterogeneity may explain the contradictory findings.Relevance to Clinical Practice: Controlled studies are needed to elucidate the true clinical benefit of targeted temperature management in improving patient outcome.
- 29 June 2020
- Published by Wiley in Nursing in Critical Care
- Vol. 27 (6) , 784-795
Open AccessTargeted temperature management in acute liver failure: A systematic review
Background: Targeted temperature management is the modern term for therapeutic hypothermia, where cooling is induced by intensive care clinicians to achieve body temperatures below 36°C. Its use in acute liver failure to improve refractory intracranial hypertension and patient outcomes is not supported by strong quality evidence.Aim: This systematic review aims to determine if targeted temperature management improves patient outcome as opposed to normothermia in acute liver failure.Methods: A computerized and systematic search of six academic and medical databases was conducted using the following keywords: “acute liver failure", “fulminant hepatic injury", “targeted temperature management", “therapeutic hypothermia", and “cooling". Broad criteria were applied to include all types of primary observational studies, from case reports to randomized controlled trials. Standardized tools were used throughout to critically appraise and extract data.Findings: Nine studies published between 1999 and 2016 were included. Early observational studies suggest a benefit of targeted temperature management in the treatment of refractory intracranial hypertension and in survival. More recent controlled studies do not show such a benefit in the prevention of intracranial hypertension. All studies revealed that the incidence of coagulopathy is not higher in patients treated with targeted temperature management. There remains some uncertainty regarding the increased risk of infection and dysrhythmias. Heterogeneity was found between study types, design, sample sizes, and quality.Conclusion: Although it does not significantly improve survival, targeted temperature management is efficient in treating episodes of intracranial hypertension and stabilizing an unstable critical care patient without increasing the risk of bleeding. It does not, however, prevent intracranial hypertension. Data heterogeneity may explain the contradictory findings.Relevance to Clinical Practice: Controlled studies are needed to elucidate the true clinical benefit of targeted temperature management in improving patient outcome.
- 1 September 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (9) , 934-936
Long-term outcome after VV ECMO: like the iceberg beneath the Titanic
- 1 September 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (9) , 934-936
Long-term outcome after VV ECMO: like the iceberg beneath the Titanic
- 12 April 2018
- Published by Springer Nature
- p. 307-330
The Patient with Severe Co-morbidities: CNS Disease and Increased Intracranial Pressure
- 12 April 2018
- Published by Springer Nature
- p. 307-330
The Patient with Severe Co-morbidities: CNS Disease and Increased Intracranial Pressure
- Open Access
- 6 September 2016
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (12) , 1727-1733
Extracorporeal membrane oxygenation and pediatric liver transplantation, “a step too far?”: Results of a single‐center experience
- 6 September 2016
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 22 (12) , 1727-1733
Open AccessExtracorporeal membrane oxygenation and pediatric liver transplantation, “a step too far?”: Results of a single‐center experience
- Open Access
- 26 October 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-8
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines. Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources. The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success. European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness. From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.
- 26 October 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-8
Open AccessCost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines. Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources. The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success. European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness. From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.
- 1 October 2014
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 28 (5) , 1307-1309
Computed Tomographic Imaging in Peripheral VA-ECMO: Where Has All the Contrast Gone?
- 1 October 2014
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 28 (5) , 1307-1309
Computed Tomographic Imaging in Peripheral VA-ECMO: Where Has All the Contrast Gone?
- Open Access
- 10 June 2014
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 20 (9) , 1141-1144
Extracorporeal membrane oxygenation for refractory hypoxemia after liver transplantation in severe hepatopulmonary syndrome: A solution with pitfalls
- 10 June 2014
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 20 (9) , 1141-1144
Open AccessExtracorporeal membrane oxygenation for refractory hypoxemia after liver transplantation in severe hepatopulmonary syndrome: A solution with pitfalls
- 20 June 2013
- Published by Wiley in Liver International
- Vol. 34 (3) , 362-366
Cerebral oedema is rare in acute‐on‐chronic liver failure patients presenting with high‐grade hepatic encephalopathy
Background & Aims: Acute‐on‐chronic liver failure (ACLF) has a rapidly progressive disease course associated with significant mortality. The prevalence of clinically significant cerebral oedema in ACLF is unknown.Methods: We aimed to describe the prevalence of cerebral oedema in a cohort of ACLF adult (>18 years). We identified patients admitted to a single, specialist intensive care unit between January 2005 and January 2011 with high‐grade hepatic encephalopathy (≥3) and a clinical picture of either ACLF or chronic liver disease (CLD). Patients who had undergone cranial CT imaging were identified and their imaging reviewed. The ACLF and CLD groups were compared.Results: One thousand and eight patients with CLD were admitted. One hundred and seventy‐three patients (110 male) underwent neuroimaging. Eighty‐one (48 male) fulfilled criteria for ACLF. Variceal bleeding (30%) and sepsis (31%) were the most frequent precipitants of ACLF. Of those with neuroimaging from the total cohort, 30% of CT scans were normal, 30% demonstrated increased cerebral atrophy for age, 17% small vessel disease and 16% intracranial haemorrhage (ICH). Cerebral oedema was seen in three patients with ACLF only. An increased prevalence of ICH was observed in the ACLF group (23% vs. 9%, P = 0.008).Conclusion: The prevalence of clinically relevant cerebral oedema was low (4%) but fatal. Death was attributable to tonsillar herniation. An increased prevalence of ICH was seen in ACLF patients and remains an important differential.
- 20 June 2013
- Published by Wiley in Liver International
- Vol. 34 (3) , 362-366
Cerebral oedema is rare in acute‐on‐chronic liver failure patients presenting with high‐grade hepatic encephalopathy
Background & Aims: Acute‐on‐chronic liver failure (ACLF) has a rapidly progressive disease course associated with significant mortality. The prevalence of clinically significant cerebral oedema in ACLF is unknown.Methods: We aimed to describe the prevalence of cerebral oedema in a cohort of ACLF adult (>18 years). We identified patients admitted to a single, specialist intensive care unit between January 2005 and January 2011 with high‐grade hepatic encephalopathy (≥3) and a clinical picture of either ACLF or chronic liver disease (CLD). Patients who had undergone cranial CT imaging were identified and their imaging reviewed. The ACLF and CLD groups were compared.Results: One thousand and eight patients with CLD were admitted. One hundred and seventy‐three patients (110 male) underwent neuroimaging. Eighty‐one (48 male) fulfilled criteria for ACLF. Variceal bleeding (30%) and sepsis (31%) were the most frequent precipitants of ACLF. Of those with neuroimaging from the total cohort, 30% of CT scans were normal, 30% demonstrated increased cerebral atrophy for age, 17% small vessel disease and 16% intracranial haemorrhage (ICH). Cerebral oedema was seen in three patients with ACLF only. An increased prevalence of ICH was observed in the ACLF group (23% vs. 9%, P = 0.008).Conclusion: The prevalence of clinically relevant cerebral oedema was low (4%) but fatal. Death was attributable to tonsillar herniation. An increased prevalence of ICH was seen in ACLF patients and remains an important differential.